Jame Abraham, MD, FACP, on Immunotherapy in Triple-Negative Breast Cancer
ASCO Post - Dec 12, 2014
Jame Abraham, MD, FACP, Director of the Cleveland Clinic Breast Oncology Program and member of the Case Comprehensive Cancer Center, offers his thoughts on abstract S1-09, "A phase Ib study of pembrolizumab (MK-3475) in patients with advanced triple-negative breast cancer," presented by Rita Nanda, MD.
Post-Transplant Adcetris Boosts PFS in Aggressive Lymphoma
MedPage Today- Dec 8, 2014
Brentuximab vedotin (Adcetris) significantly improved progression-free survival (PFS) in Hodgkin lymphoma patients who had undergone autologous stem-cell transplant, researchers said here...Hillard Lazarus, MD, Professor of Medicine at Case Western Reserve University (CWRU) and member of the Case Comprehensive Cancer Center in Cleveland, called the results "practice changing." "For patients with Hodgkin lymphoma, we use this agent a lot to get them to transplant," he told MedPage Today. "Adding this antibody to the practice of medicine is going to result in more cures, I believe, and certainly in more disease survivors in patients with Hodgkin lymphoma."
Gerson: Novel Gene Therapy for Glioma
Cancer Therapy Advisor- Dec 7, 2014
Stanton Gerson, MD, Director of the Case Comprehensive Cancer Center and Seidman Cancer Center, discusses study findings that looked into a novel genetic therapy for patients with glioma. He presented his study at the American Society of Hematology 2014 meeting.
Caimi: Methoxyamine for Chronic Leukemia
Cancer Therapy Advisor- Dec 7, 2014
Dr. Paolo Caimi, University Hospitals Seidman Cancer Center and member of the Case Comprehensive Cancer Center in Cleveland, discusses phase I trial results for methoxyamine at the American Society of Hematology 2014 meeting in San Francisco.
Research Sheds Light on Ethnic Discrepancies in CLL
Cleveland Clinic Consult QD- Dec 5, 2014
A recent study published in the journal Blood, headed by investigators at Cleveland Clinic and performed in collaboration with the National Marrow Donor Program, suggests a novel and important linkage between CLL, ethnic background and certain immune system proteins called human leukocyte antigen (HLA) alleles. HLA is essentially the defining antigens on our immune cells that do many things, including regulating our immune system and protecting us from infection, explains Brian T. Hill, MD, PhD the study's lead author, oncologist at the Taussig Cancer Institute, and member of the Case Comprehensive Cancer Center.. "The thing that's unique about HLA molecules is that there are many different varieties, and those varieties are specific to ethnic populations. So the HLA of someone from Northern European ancestry is specific and different from those of, say, African or Asian ancestry."
Nilotinib (Tasigna) and Chemotherapy for First-Line Treatment in Elderly patients with de novo Philadelphia Chromosome/BCR-ABL1 Positive ALL
MedPage Today - Dec 2014
Commentary by Stanton Gerson, MD, Director of the Case Comprehensive Cancer Center and Seidman Cancer Center.
Distelhorst Named 2015 Harrington Scholar-Innovator
Clark Distelhorst, MD, PhD, Professor in the Division of Hematology/Oncology at CWRU and University Hospitals Case Medical Center (UHCMC), was recently named a 2015 Harrington Scholar-Innovator by the Harrington Discovery Institute (HDI) at UHCMC. Dr. Distelhorst is one of 11 outstanding physician-scientists in the nation to receive the award, which provides funding and drug development to help bring their research from basic discovery to clinical introduction.
As a recipient of this award, Dr. Distelhorst will receive up to $700,000 over two years to support his research on blood cancer. In addition, he along with his fellow Scholar-Innovators will be given access to HDI's Innovation Support Center, which includes a renowned group of industry experts charged with helping guide drug development.
Vinayak Honored as Master Clinician
Shaveta Vinayak, MD, Assistant Professor in the Division of Hematology/Oncology at CWRU and UHCMC, was honored as the inaugural Becky Hennessy Endowed Master Clinician in Breast Cancer Genomics. This endowment recognizes Dr. Vinayak's excellence in patient care and accomplishments, dedication, and clinical research focus on genomic approaches to breast cancer treatment.
First Gene Associated with Familial Glioma Identified
A study conducted by the Gliogene Consortium, an international consortium of researchers, has identified for the first time a gene associated with familial glioma,providing new support that certain people may be genetically predisposed to the disease. Study authors found an increased risk of cancer associated with mutations in the POT1 gene. The findings were published last week in the Journal of the National Cancer Institute.
"This discovery is tremendously exciting, as we have known for years that a small subset of families have multiple people with gliomas, yet we have not understood the potential causes," commented study collaborator, Dr. Jill Barnholtz-Sloan. "This new paper sheds light on a potential cause for some of these families." Dr. Barnholtz-Sloan, Associate Director for Bioinformatics at the Case Comprehensive Cancer Center and Associate Professor in the Division of General Medical Sciences (Oncology) at CWRU, recruited families to the study and is the Ohio Principal Investigator for the Gliogene Consortium.
New Biographical Sketch Format Required for NIH and AHRQ Grant Applications Submitted for Due Dates on or After May 25, 2015
The National Institutes of Health (NIH) Agency for Healthcare Research and Quality's (AHRQ) will require use of a new biosketch format in applications for research grantssubmitted for due dates on or after May 25, 2015. Between now and that time, applicants will have the choice of using the old or new biosketch format. This Notice supersedes NOT-OD-15-024 about the NIH and AHRQ requirement for use of a new biosketch format and provides some latitude in the transition for those who have already been compiling biosketches for their large grant applications with deadlines in early in 2015.
NIH and AHRQ encourages applicants to use the newly published biosketch format for all grant and cooperative agreement applications submitted for due dates on or after January 25, 2015, and will require use of the new format for applications submitted for due dates on or after May 25, 2015. Applicants may submit using the new biosketch format for due dates before January 25, 2015, if they wish.
Radiation Resources Core Facility Adds Small Animal Irradiation Capabilities
The Radiation Resources Core Facility is now capable of irradiating small animals (rodents) on clinical radiation devices, including Cyberknife and Gammaknife. The added benefit is the capacity to deliver focal radiation while sparing normal tissues, more closely mimicking patient treatments and expanding the translational impact of animal experimentation. Please inquire as to how we can improve your experimental designs. Visit the Radiation Resources Core Facility for contact information.
The Kure It-AACR Research Grant for Immunotherapy in Kidney Cancer represents a joint effort to promote and support innovative cancer research. This grant is available to full time, independent junior and senior investigators to study immunological aspects of, or treatments for, kidney cancer. Research projects should advance the basic knowledge of tumor immunology mechanisms, or develop new concepts in the treatment, control, or prevention of kidney cancer by immunology-based therapeutic approaches. Proposed projects may be basic, translational, clinical or epidemiological in nature and must focus on cancer immunology including, but not limited to: immune recognition, regulation, tumor escape, and therapeutic manipulation for kidney cancer.
Deadline: January 5, 2015
The AACR-Ocular Melanoma Foundation Fellowship, in honor of Robert C. Allen, MD represents a joint effort to encourage and support a postdoctoral or clinical research fellow to conduct ocular/uveal melanoma research and to establish a successful career path in ophthalmology, ocular oncology, uveal melanoma cancer biology or similar field. The research proposed for funding may be basic, translational or clinical in nature and must have direct, primary applicability and relevance to ocular/uveal melanoma.
Deadline: January 12, 2015
The Breast Cancer Research Foundation-AACR Career Development Awards for Translational Breast Cancer Research represent a joint effort to promote and support innovative research designed to accelerate the discovery, development, and application of new agents to treat breast cancer and/or for pre-clinical research with direct therapeutic intent. Eligibility is limited to junior faculty who, at the start of the grant term, will have completed their most recent doctoral degree or medical residency within the past 11 years. The research proposed for funding must be translational in nature and must have direct applicability and relevance to breast cancer.
Deadline: January 20, 2015
The AACR-Triple Negative Breast Cancer Foundation Career Development Award for Clinical/Translational Researchrepresents a joint effort to encourage and support junior faculty to conduct triple negative breast cancer research and establish a successful career path in this field. Eligibility is limited to junior faculty who, at the start of the grant term, will have completed their most recent doctoral degree or medical residency within the past 11 years. The research proposed for funding must be clinical or translational in nature and must have direct applicability and relevance to triple negative breast cancer.
Deadline: January 27, 2015
The Debbie's Dream Foundation-AACR Gastric Cancer Research Fellowships represent a joint effort to encourage and support postdoctoral or clinical research fellows to conduct gastric cancer research and to establish a successful career path in this field. The research proposed for funding may be basic, translational, clinical, or epidemiological in nature and must have direct applicability and relevance to gastric cancer.
Deadline: January 27, 2015
Bladder Cancer Advocacy Network
The Bladder Cancer Advocacy Network is accepting applications for the Bladder Cancer Research Innovation Award. This new award, supported by the James Family Foundation, in conjunction with Partner Fund Management, which will support the work of one investigator with an exceptionally novel and creative project with great potential to produce a breakthrough in the management of bladder cancer. The aim of the Bladder Cancer Research Innovation Award is to support exceptionally novel and creative projects with great potential to produce breakthroughs in the management of bladder cancer. Proposals will be accepted for creative ideas and innovative approaches that have direct application and relevance to bladder cancer.
LOI Deadline: January 14, 2015
Avon Foundation for Women Breast Cancer Research 2015 Program
The Avon Foundation for Women continues its search for new preventive strategies to address the growing number of breast cancer cases around the globe and increase our understanding of not only the causes of breast cancer, but also the development and treatment of metastatic disease. The 2015 Avon Foundation Research Program seeks proposals in these areas.
Deadline: January 15, 2015
Alex's Lemonade Stand Foundation Epidemiology Grants Epidemiology Grants
Leukemia & Lymphoma Society Translational Research Program (TRP)
Support of Multi-investigator Initiatives in the Case CCC
HELP US HELP YOU!
If you have a new grant, recently won an award, or have other newsworthy items, please let us know so we can publicize them in the newsletter and other media outlets. You deserve the accolades! Send items to Gillian Irwin at firstname.lastname@example.org.